[Correspondence] Optimising standard of care in non-small-cell lung cancer trials
Source 柳叶刀 Lancetjust now
Summary
We read Anwen Xiong and colleagues’ study with great interest.1 Despite the established first-line role of immune checkpoint inhibitors in advanced non-small-c…
We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.
Open original- Desk
- Health
- Region
- United Kingdom
- Language
- English
- Item ID
- health-a015949f
Comments 0 comments
No comments yet. Be the first.